Camurus’ Full Year Report 2021
“Strong fourth quarter, with record sales, new regulatory submission and good progress in our pipeline and partnerships” Fourth quarter and full year summary October – December · Total revenues amounted to SEK 183 (106) million, an increase of 73% (70% at CER1), whereof product sales were SEK 181 (104) million, up 74% (71% at CER) · Quarter on quarter sales growth was 19% (18% at CER) · Operating result was SEK -18 (-82) million, an improvement of 78% · Cash position at the end of the quarter was SEK 412 (462) million · The European Medicines Agency accepted and